Breast cancer molecular typing and risk assessment method based on mRNA expression

Abstract

The invention discloses a breast cancer molecular typing and risk assessment method based on mRNA expression, and particularly relates to the technical field of medical treatment. The method comprises the following specific steps: step 1, extracting total RNA in a breast cancer paraffin specimen by adopting a Qiagen FFPE RNA extraction kit; 2, measuring the total RNA concentration. The method comprises the following steps: carrying out hybridization reaction on an mRNA quantitative probe and a target RNA sequence, sealing a film on a hybridization reaction product, putting the hybridization reaction product into a nanoString digital fluorescent bar code single-molecule analyzer, and carrying out gene expression detection through a program set in advance; then carrying out quantitative analysis on the expression quantities of the HER2 gene, the ESR1 gene, the PGR gene and the Ki-67 gene by adopting nSolver software; then, various specimens are subjected to luminal type molecular typing, HER2 + type molecular typing and triple-negative type molecular typing according to set thresholds, luminal types are further divided into luminal A type molecular typing and luminal B type molecular typing and HER2 type molecular typing are further divided into luminal B-HER2 + type molecular typing and HER2 + type molecular typing according to the threshold of CTSL2, and an ER + positive prognosis model is established, so that low-risk people can be accurately predicted, and treatment is avoided.

Description

technical field [0001] The invention relates to the field of medical technology, in particular to a method for molecular typing and risk assessment of breast cancer based on mRNA expression. Background technique [0002] Breast cancer is a highly heterogeneous tumor, and the traditional pathomorphological classification has gradually shown its incompleteness in current clinical practice. With the completion of the Human Genome Project and the application of molecular biology techniques, the concept of molecular typing based on tumor morphology combined with gene expression features has been recognized by scholars. Common molecular subtypes of breast cancer include: Luminal A type, Luminal B type, Her-2 overexpression type and Basal-like type. Among them, Luminal A type: is the most common molecular subtype of breast cancer, with an incidence rate of 44.5%-69.0%. ER+ and / or PR+, Her-2-, have the best prognosis. Endocrine therapy works best. Endocrine therapy (± chemothera...

AI Technical Summary

Problems solved by technology

[0004] The existing technology has the following deficiencies: in the molecular typing of breast cancer, the existing molecular typing of breast cancer is based on protein expression, such as immunohistochemical method, the interpretation of this method is mostly based on artificial, artificial subjectivity in interpretation It is easy to affect the interpretation results during the process, especially the interpretation of borderline cases. Secondly, protein expression cannot be absolutely quantified

In the risk assessment of luminal breast cancer, the current risk of breast cancer recurrence is calculated based on the RT-PCR method. In the calculation process, there are problems such as large amount of starting RNA, complicated operation, long time period, and molecular typing detection cannot be performed at the same time. question

Images